Feature | HRS | May 20, 2020

Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

The latest science in EP to treat cardiac arrythmias 

HRS 2020 Late-Breaking Clinical Trials in Electrophyiology

May 20, 2020 — Here is the complete list of late-breaking clinical trials (LBCT)  and links to articles on all of them from the Heart Rhythm Society (HRS) 2020 virtual meeting. The in-person meeting was cancelled this year because of the continuing COVID-19 containment efforts. The presentations are divided into four LBCT sessions, which are all available on demand on Heart Rhythm 365 available at www.hrsonline.org/HRS2020Science starting on Friday, May 8, 2020, as well as in the Heart Rhythm Journal May Issue Supplement.

 

Friday, May 8, 2020

HRS Late-Breaking Clinical Trials - Randomized Trials

Etripamil Nasal Spray For Acute Termination Of Spontaneous Episodes Of Paroxysmal Supraventricular Tachycardia (Node-301 Trial). Bruce S. Stambler. M.D., FHRS, Piedmont Heart Institute, Atlanta, Ga.

A Randomized Trial Of Subcutaneous Versus Transvenous Defibrillator Therapy: The PRAETORIAN Trial. Reinoud Knops, M.D. Ph.D., Academic Medical Center, Hilversum, Netherlands 

Convergence Of Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Persistent AF. David De Lugio, M.D., FHRS, Emory Saint Joseph`s Hospital, Atlanta, Ga. 

Persistent Atrial Fibrillation Ablation With a Contact Force Sensing Catheter: The Prospective Multicenter PRECEPT Trial with the Thermocool Smarttouch SF Catheter. Moussa Mansour, M.D., FHRS, Massachusetts General Hospital, Boston, Mass.

Smart Watches Significantly Improve Adherence To Oral Anticoagulation Therapy Among Patients With Atrial Fibrillation. Zhan Shi, M.D., Beijing Chao-yang Hospital, Capital Medical University, Beijing, China

HRS Late-Breaking Clinical Trials - Innovation Boulevard

Left Bundle Branch Pacing As A Novel Strategy For Cardiac Resynchronization Therapy: Results From International LBBP Collaborative Study Group. Pugazhendhi Vijayaraman, M.D., FHRS, Geisinger Heart Institute, Mountain Top, Penn.

Longer Term Results From A Phase I/II Study Of EP-guided Noninvasive Cardiac Radioablation For Treatment Of Ventricular Tachycardia (ENCORE-VT). Philip Cuculich, M.D., Washington University, St. Louis, Mo. 

VIDEO: Cardiac Radiotherapy Ablation to Treat Ventricular Tachycardia — Interview with Clifford Robinson, M.D.

Pulsed AF: First Human Experience And Acute Procedural Outcomes Using A Novel Pulsed Field Ablation System. Atul Verma, M.D., FHRS, Southlake Regional Health Center, Toronto, Onterio, Canada

Point-by-point Pulsed Field Ablation (+/- Radiofrequency Ablation) To Treat Atrial Fibrillation: A First-in-human Trial. Vivek Y. Reddy, M.D., Icahn School of Medicine at Mount Sinai, New York, N.Y.

Understanding Outcomes With The S-ICD In Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial Primary Results. Michael R. Gold, M.D., Ph.D., FHRS, Medical University of South Carolina, Charleston, S.C. 

 

Saturday May 9, 2020

HRS Late-Breaking Clinical Trials - All About AFib

Improving Esophageal Protection During AF Ablation With Ablation Index Technology: Outcomes From The Impact Study. Mark M. Gallagher, M.D., St George's Hospital Medical School, London, U.K.

Incidence Of Silent Brain Infarcts In Anticoagulated Patients With Atrial Fibrillation in Swiss-AF Study. David Conen, M.D., MPH, McMaster University, Hamilton, Ontario, Canada

Primary Outcome Evaluation Of A Next Generation Left Atrial Appendage Closure Device: The PINNACLE FLX Trial. Shephal K Doshi, M.D., Pacific Heart Institute, Santa Monica, Calif.

Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study. Nazem Akoum, M.D., MS, FHRS, University of Washington, Seattle, Wash.

Active Extracellular Matrix Remodeling Prepares The Heart For Future Atrial Fibrillation. First Results Of The PREDICT-AF Trial. Joris R. de Groot, M.D., Ph.D., Amsterdam UMC, Amsterdam, Netherlands

 

HRS Late-Breaking Clinical Trials - This Could Change My Practice

Comparison Of Outcomes Among Patients Implanted With A Tined, Leadless Versus Transvenous Single-chamber Ventricular Pacemaker In The Novel Micra Coverage With Evidence Development Study. Jonathan P. Piccini, M.D., MHS, FHRS, Duke University Medical Center, Durham, N.C.

Predicted Benefit Of The Implantable Cardioverter Defibrillator: The MADIT-ICD Benefit Score. Arwa Younis, M.D., University of Rochester Medical Center, Rochester, N.Y. 

Assessment Of Absolute Risk Of Life-threatening Cardiac Events In Long QT Syndrome Patients. Wojciech Zareba, M.D., Ph.D., University of Rochester Center, Rochester, N.Y.

Ablation Of Refractory Ventricular Tachycardia With A Heated-saline Needle Catheter For Enhanced Radiofrequency (SERF) Ablation With Creation Of Transmural Lesions: A First-in-man Feasibility Study. Douglas L Packer, M.D., FHRS, Mayo Clinic-St. Mary`s Hospital, Rochester, Minn.

Performance Of First In The World Pacemaker To Use Smart Device App For Remote Monitoring. Khaldoun G. Tarakji, M.D., MPH, FHRS, Cleveland Clinic, Cleveland, Ohio

 

Other Heart Rhythm 2020 News:

VIDEO: Cardiac Radiotherapy Ablation to Treat Ventricular Tachycardia — Interview with Clifford Robinson, M.D.

Frequent Coffee Consumption Lowers Chance of Arrhythmias

VIDEO: Why QT-prolongation Occurs in COVID-19 Patients on Hydroxychloroquine and Azithromycin — Interview with Andrew Krahn, M.D.

FDA Clears HeartLight X3 Laser Ablation System to Treat Atrial Fibrillation

VIDEO: Top New EP Technologies at Heart Rhythm Society 2020 — Interview with Andrew Krahn, M.D.

FDA Approves Medtronic Cobalt and Crome ICD Portfolio

VIDEO: Insights Into How HRS Organized its Virtual Meeting — Interview with Andrew Krahn, M.D.

 

Related Recent Late-breaking Cardiology Trial Presentations:

Heart Rhythm Society 2019 Late-Breaking Clinical Trials

ACC 2020 Late-breaking Presentations

TCT 2019 Late-breaking Presentations

American Heart Association 2019 Late-breaking Trials
 

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve